WuXi XDC Achieves GMP Release for Singapore Bioconjugate Production Line
- WuXi XDC's Singapore BCM3 line achieved GMP release for antibody intermediates and conjugated drug substances, supporting batches up to 2,000 L.
- The facility represents WuXi XDC's first overseas GMP-released manufacturing site, completed in 2.5 years from design through qualification.
- A DP4 drug-product filling line at the same Singapore site is targeted for GMP release by end of August 2026.
Operational Impact
WuXi XDC's Singapore GMP release expands APAC bioconjugate manufacturing capacity and geographic redundancy, enabling commercial-scale dual sourcing for clients seeking regional supply-chain resilience.
Source: PharmaSource RSS